Data from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Autor: Sjoerd H. van der Burg, Cornelis J.M. Melief, Hans W. Nijman, Theo Stijnen, Gemma G. Kenter, Tjalling Bosse, Gertjan J. Fleuren, J. Hanneke N.G. Oude Elberink, Jaap Oostendorp, A. Rob P.M. Valentijn, Harry Hollema, Toos Daemen, Lorraine M. Fathers, J. Baptist M.Z. Trimbos, Marjolein J. Kagie, Henk W. Schreuder, Marc van Beurden, Bart W.J. Hellebrekers, Edith M.G. van Esch, Ineke L.E. Hamming, Margriet J.G. Löwik, Dorien M.A. Berends-van der Meer, Nikki M. Loof, Linda F.M. Stynenbosch, Renee Vermeij, Marij J.P. Welters, Mariëtte I.E. van Poelgeest

Purpose: Therapeutic vaccination with human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides (SLP) is effective against HPV16-induced high-grade vulvar and vaginal intraepithelial neoplasia (VIN/VaIN). However, clinical nonresponders

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90fd8ad0b57ff48e3408370a9dbd37d4
https://doi.org/10.1158/1078-0432.c.6524177.v1

2022-RA-637-ESGO Five-year universal tumor screening ofBRCA1/2in epithelial ovarian carcinoma;is histotype-directed hr-deficiency testing justified?

Autor: Claire JH Kramer, Lieke Lanjouw, Arja ter Elst, Nienke Solleveld-Westerink, Hans M Hazelbag, Marjolein J Kagie, Els JM Ahsmann, Annemieke H van der Hout, Nienke van der Stoep, Cor D de Kroon, Katja N Gaarenstroom, Tom van Wezel, Lieke PV Berger, Vincent THBM Smit, Truuske H de Bock, Christi J van Asperen, Marian JE Mourits, Maaike PG Vreeswijk, Joost Bart, Tjalling Bosse

Publikováno v: Ovarian cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4b7d1bc3f3939fd14990dd4e0c103c4
https://doi.org/10.1136/ijgc-2022-esgo.532

142 Low preoperative skeletal muscle density predicts postoperative complications and functional decline in older women with ovarian cancer

Autor: Marjolein J. Kagie, B. C. van Munster, F Van den Bos, C.D. de Kroon, N J van Soolingen, AMLDVan Haaften-de Jong, Alain R. Viddeleer, S Oei, E. Souwer, Johannes W. Trum, Frédéric Amant, V Van der Zanden, Astrid Baalbergen, J.E.A. Portielje, D. Houtsma, Mje Mourits

Publikováno v: Miscellaneous.

Introduction/Background* Insights in how to select older patients who can benefit from standard care and patients that need adjusted treatment are necessary. This study aims to determine the predictive value of lumbar skeletal muscle mass and density

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::935c0d3d6b508b3cb44f1b10f79d3a03
https://doi.org/10.1136/ijgc-2021-esgo.251

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Autor: J Hanneke N G Oude Elberink, Marij J. P. Welters, Marjolein J. Kagie, Nikki M. Loof, Theo Stijnen, Linda F. M. Stynenbosch, Bart W. J. Hellebrekers, Marc van Beurden, Margriet J. G. Löwik, A. Rob P. M. Valentijn, Ineke E. Hamming, Sjoerd H. van der Burg, Tjalling Bosse, Henk W.R. Schreuder, Dorien M A Berends-van der Meer, Hans W. Nijman, Mariëtte I.E. van Poelgeest, Edith M G van Esch, Renee Vermeij, Gert Jan Fleuren, Toos Daemen, J. Baptist Trimbos, Cornelis J. M. Melief, Harry Hollema, Lorraine M. Fathers, Gemma G. Kenter, Jaap Oostendorp

Publikováno v: Clinical cancer research, 22(10), 2342-2350. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(10), 2342-2350. AMER ASSOC CANCER RESEARCH
van Poelgeest, M I E, Welters, M J P, Vermeij, R, Stynenbosch, L F M, Loof, N M, Berends-van der Meer, D M A, Lowik, M J G, Hamming, I L E, van Esch, E M G, Hellebrekers, B W J, van Beurden, M, Schreuder, H W, Kagie, M J, Trimbos, J B M Z, Fathers, L M, Daemen, T, Hollema, H, Valentijn, A R P M, Oostendorp, J, Oude Elberink, H N G, Fleuren, G J, Bosse, T, Kenter, G G, Stijnen, T, Nijman, H W, Melief, C J M & van der Burg, S H 2016, ' Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response ', Clinical Cancer Research, vol. 22, no. 10, pp. 2342-2350 . https://doi.org/10.1158/1078-0432.CCR-15-2594
Clinical Cancer Research, 22(10), 2342. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(10), 2342-2350. American Association for Cancer Research Inc.

Purpose: Therapeutic vaccination with human papillomavirus type 16 (HPV16) E6 and E7 synthetic long peptides (SLP) is effective against HPV16-induced high-grade vulvar and vaginal intraepithelial neoplasia (VIN/VaIN). However, clinical nonresponders

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0019df04b3e776a79539df40f209528
https://doi.org/10.1158/1078-0432.ccr-15-2594

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

Autor: Linda F. M. Stynenbosch, Marjolein J. Kagie, Bart W. J. Hellebrekers, Tamara H. Ramwadhdoebe, Peggy J. de Vos van Steenwijk, Margriet J. G. Löwik, Mariette I.E. van Poelgeest, Elisabeth M. Osse, Gert Jan Fleuren, Nikki M. Loof, A. Rob P. M. Valentijn, Linda S. Nooij, Jaap Oostendorp, Marij J. P. Welters, Caroline E. van der Minne, Gemma G. Kenter, Sjoerd H. van der Burg, Dorien M A Berends-van der Meer, Lorraine M. Fathers, Cornelis J. M. Melief

Publikováno v: Cancer Immunology, Immunotherapy, 63(2), 147-160

The capacity of a low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) to induce an HPV16-specific T-cell response as well as to establish long-term immunologic memory in patients with low-grade abnormalities of the cervix was determined in a pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1be1718c8e7e848db6c4c06f450f2ce
https://doi.org/10.1007/s00262-013-1499-2